BR0010700A - Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata - Google Patents

Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata

Info

Publication number
BR0010700A
BR0010700A BR0010700-0A BR0010700A BR0010700A BR 0010700 A BR0010700 A BR 0010700A BR 0010700 A BR0010700 A BR 0010700A BR 0010700 A BR0010700 A BR 0010700A
Authority
BR
Brazil
Prior art keywords
conjugates
polyamine
therapies
quinone
cancers
Prior art date
Application number
BR0010700-0A
Other languages
English (en)
Inventor
Benjamin Frydman
Laurence J Marton
Original Assignee
Slil Biomedical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slil Biomedical Corp filed Critical Slil Biomedical Corp
Publication of BR0010700A publication Critical patent/BR0010700A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/13—Amines containing three or more amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/18—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "CONJUGADOS ANáLOGOS DE POLIAMINA E CONJUGADOS DE QUINONA COMO TERAPIAS PARA CâNCERES E DOENçAS NA PRóSTATA". São fornecidos conjugados peptídicos em que agentes citocidas e citostáticos, tais como análogos de poliamina ou naftoquinonas, são conjugados em um polipeptídeo reconhecido e clivado por enzimas tais como o antígeno específico à próstata (PSA) e a catepsina B, assim como composições que compreendem estes conjugados. São também fornecidos processos para a utilização destes conjugados no tratamento de doenças da próstata.
BR0010700-0A 1999-04-30 2000-04-27 Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata BR0010700A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13180999P 1999-04-30 1999-04-30
PCT/US2000/011542 WO2000066175A2 (en) 1999-04-30 2000-04-27 Conjugates as therapies for cancer and prostate diseases

Publications (1)

Publication Number Publication Date
BR0010700A true BR0010700A (pt) 2002-02-13

Family

ID=22451123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010700-0A BR0010700A (pt) 1999-04-30 2000-04-27 Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata

Country Status (9)

Country Link
US (4) US20040006049A1 (pt)
EP (1) EP1173223A2 (pt)
JP (2) JP2002543163A (pt)
AU (1) AU4678300A (pt)
BR (1) BR0010700A (pt)
CA (1) CA2368801A1 (pt)
IL (2) IL146126A0 (pt)
MX (1) MXPA01011008A (pt)
WO (1) WO2000066175A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146126A0 (en) * 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
DE60029944T2 (de) 1999-04-30 2007-04-05 Cellgate, Inc., Redwood City Polyamine und ihre therapeutische verwendung
EP1574507A3 (en) * 1999-04-30 2005-10-26 SLIL Biomedical Corporation Furo- and pyrano-naphthoquinones and their use in the treatment of cancer
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
WO2002092792A2 (de) * 2001-05-16 2002-11-21 Genethor Gmbh Antigen-abhängige reduktion von spezifischen immunreaktionen durch beeinflussung der co-stimulation
US20030130356A1 (en) * 2001-10-16 2003-07-10 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
CA2469354A1 (en) 2001-12-07 2003-06-19 Slil Biomedical Corporation Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
EP1877097B1 (en) 2004-08-11 2012-06-20 Arqule, Inc. Aminoacid conjugates of beta-lapachone for tumor targeting
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
BRPI0517551A (pt) * 2004-10-04 2008-10-14 Cellgate Inc análogos de poliamina como agentes terapêuticos para doenças oculares
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US20070232677A1 (en) * 2006-03-14 2007-10-04 Marton Laurence J Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
JP2010502765A (ja) * 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
ES2532656T3 (es) 2007-04-30 2015-03-30 Arqule, Inc. Compuestos de hidroxi sulfonato de quinona y sus usos
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP2015013811A (ja) * 2011-10-28 2015-01-22 石原産業株式会社 アリールアミジン誘導体又はその塩を含有する植物病害防除剤
PT2822936T (pt) 2012-03-07 2021-12-02 Univ Of Delhi Derivados da aminoquinolina e suas utilizações
US11421097B2 (en) 2012-12-20 2022-08-23 Henkel Ag & Co. Kgaa Container sealant composition
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
JP6807831B2 (ja) 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
CN111840298A (zh) * 2019-04-26 2020-10-30 湖北工业大学 小分子抑制剂在制备抑制鸟氨酸脱羧酶与鸟氨酸脱羧酶抗酶1的相互作用的制药用途
US12428658B2 (en) 2019-11-25 2025-09-30 The General Hospital Corporation Methods and compositions for enzymatic polymerization of N3′→P5′ phosphoramidate DNA

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440724A (en) 1944-10-27 1948-05-04 Commercial Solvents Corp Nu-substituted, 2-butene-1, 4-diamines, and process for preparing
CH413364A (de) 1959-04-22 1966-05-15 Geigy Ag J R Verfahren zur Herstellung von oxydationsbeständigen Polyamiden
JPS4530077Y1 (pt) 1969-02-12 1970-11-18
US4013507A (en) 1973-09-18 1977-03-22 California Institute Of Technology Ionene polymers for selectively inhibiting the vitro growth of malignant cells
US3956502A (en) 1974-09-04 1976-05-11 Nalco Chemical Company Polyamine alcohols as microbiocides
US4035174A (en) * 1975-10-09 1977-07-12 Merck & Co., Inc. Novel dibicyclo [3.1.1] and [2.2.1] heptyl and dibicyclo [3.1.1] and [2.2.1] heptenyl polyamines and methods for their preparation
SE417569B (sv) * 1975-10-22 1981-03-30 Kemanobel Ab Vissa angivna blandningar av guaniderade alifatiska polyaminer, eller deras syraadditionssalter till anvendning som pesticid och antimikrobiellt medel
US4153567A (en) * 1977-11-10 1979-05-08 Milliken Research Corporation Additives for lubricants and fuels
US4273706A (en) * 1979-01-09 1981-06-16 Eastman Kodak Company Nondiffusible heterocyclylazonaphthol dye-releasing compounds
US4491651A (en) * 1982-05-17 1985-01-01 Petrolite Corporation Antistats containing acrylonitrile copolymers and polyamines
US4537601A (en) * 1982-05-17 1985-08-27 Petrolite Corporation Antistats containing acrylonitrile copolymers and polyamines
US4661509A (en) 1982-09-28 1987-04-28 Gordon Arnold Z Methods for treating leukopenia
US4577636A (en) * 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US4590288A (en) * 1983-06-29 1986-05-20 Exxon Research And Engineering Co. Bi- or polymetallic coordination complex
US4551550A (en) 1983-12-06 1985-11-05 Merrell Dow Pharmaceuticals Inc. N-2,3-Butadienyl-1,4-butanediamine derivatives
DE3401675A1 (de) * 1984-01-19 1985-07-25 Bayer Ag, 5090 Leverkusen Neue polyamine und ein verfahren zu ihrer herstellung
US4767611A (en) * 1984-07-03 1988-08-30 Gordon Robert T Method for affecting intracellular and extracellular electric and magnetic dipoles
CA1247598A (en) 1984-12-27 1988-12-28 Harry J. Andress, Jr. Compounds containing amide linkages from mono-and polycarboxylic acids in the same molecule and lubricants and fuels containing same
KR910009202B1 (ko) * 1985-10-23 1991-11-04 니혼메디피직스 가부시끼가이샤 포르피린 유도체의 제조방법
CS252771B1 (cs) 1986-01-20 1987-10-15 Josef Urbanek Reakční produkty vyšších nasycených a/nebo nenasycených karboxylových kyselin s polytopickými aminy
US4698446A (en) * 1986-07-01 1987-10-06 The Bf Goodrich Company Synthesis of polyamines and mixture formed thereby, of diprimary polyalkylene polyamines with disubstituted N-adjacent terminal carbon atom(s)
DE3783532T2 (de) 1986-07-28 1993-07-22 Eastman Kodak Co Zusammensetzung und verfahren, die substituierte ortho-chinone als elektronen-transfermittel in analytischen bestimmungen verwenden.
US4963565A (en) * 1986-07-30 1990-10-16 National Jewish Center For Immunology And Respiratory Medicine In vivo treatment of mycobacterial infections with 6-cyclo octylamino-5,8-quinoline quinone
CA1302275C (en) * 1986-08-07 1992-06-02 Yuji Narutomi Enzyme inhibitor
EP0265387B1 (en) * 1986-10-23 1995-11-15 Ciba-Geigy Ag Method of forming images
US4889851A (en) 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US5091576A (en) 1986-12-02 1992-02-25 University Of Florida Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5393757A (en) 1986-12-02 1995-02-28 University Of Florida Polyamines and anti-diarrheal and gastrointestinal anti-spasmodic pharmaceutical compositions and methods of treatment
US6184232B1 (en) 1986-12-02 2001-02-06 University Of Florida Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment
US5677351A (en) 1986-12-02 1997-10-14 University Of Florida Research Foundation, Inc. Sterically hindered tetraamines and method for their production
US5342945A (en) * 1986-12-02 1994-08-30 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
USRE38417E1 (en) 1986-12-02 2004-02-03 University Of Florida Research Foundation, Inc. Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
US5120843A (en) * 1987-04-27 1992-06-09 Upjohn Pharmaceutically active amines
US5654484A (en) 1987-10-08 1997-08-05 Merrell Pharmaceuticals Inc. Polyamine derivatives as antineoplastic agents
US4868219A (en) 1988-04-07 1989-09-19 Thornfeldt Carl R Treatment of skin diseases with aliphatic amines
US5284647A (en) * 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
JPH027419A (ja) 1988-06-24 1990-01-11 Toshiba Mach Co Ltd 気相成長装置
US5344435A (en) * 1988-07-28 1994-09-06 Bsd Medical Corporation Urethral inserted applicator prostate hyperthermia
US4935449A (en) * 1988-08-04 1990-06-19 Merrell Dow Pharmaceuticals Inc. N-2,3-butadienyl tri- and tetraaminoalkane derivatives
CA2011367C (en) 1988-08-30 1997-07-08 Henry Ashjian Reaction products of alkenyl succinimides with ethylenediamine carboxy acids as fuel detergents
US5374658A (en) * 1988-10-26 1994-12-20 Ortho Phamaceutical Corporation Use of oxidized polyamines, especially NN'-bis-(3-propionaldehyde)-1-4-diaminobutane (spermine dialdehye) in graft treatment
US5719193A (en) 1989-05-23 1998-02-17 Merrell Pharmaceuticals, Inc. Method of potentiating cell-mediated immunity utilizing polyamine derivatives
US4959356A (en) * 1989-05-26 1990-09-25 The United States Of America As Represented By The United States Department Of Energy Porphyrins for boron neutron capture therapy
US5007437A (en) * 1989-06-16 1991-04-16 Mmtc, Inc. Catheters for treating prostate disease
US5021571A (en) * 1989-06-29 1991-06-04 Associated Universities, Inc. Cyclohexyl EDTA monoanhydride
US5283367A (en) 1989-08-30 1994-02-01 Ciba-Geigy Corporation Substituted 1,4-diamino-2-butene stabilizers
FI102273B (fi) * 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
JP3007391B2 (ja) 1990-08-13 2000-02-07 花王株式会社 新規第４級アンモニウム化合物
US5776458A (en) * 1990-12-05 1998-07-07 Pharmacia & Upjohn S.P.A. Anthracycline-conjugates
US5561136A (en) * 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
US5354782A (en) * 1991-01-17 1994-10-11 Merrell Dow Pharmaceuticals Inc. Polyamine phenols as radioprotective agents
US5217964A (en) * 1991-01-23 1993-06-08 Merrell Dow Pharmaceuticals Inc. Polyamine thiols as radioprotective agents
US5563262A (en) * 1991-03-28 1996-10-08 University Of Toledo Diels alder adducts of vinyl porphyrins
US5587394A (en) * 1991-03-28 1996-12-24 The University Of Toledo Production and use of diels alder adducts of vinyl porphyrins, of metal complexes thereof, and of compositions containing such adducts and complexes
US5354858A (en) * 1991-03-28 1994-10-11 The University Of Toledo Production and use of Diels Alder adducts of vinyl porphyrins and of compositions containing such adducts
GB9111794D0 (en) 1991-05-31 1991-07-24 Robins David J Antifungal compounds
BR9206403A (pt) 1991-08-23 1994-12-27 Pfizer Aril-poliaminas sintéticas como antagonistas de neurotransmissores aminoácidos excitadores
US5185369A (en) 1991-08-23 1993-02-09 Pfizer Inc. Synthetic heteroaryl polyamines as excitatory amino acid neurotransmitter antagonists
JP2684473B2 (ja) * 1991-09-02 1997-12-03 富士写真フイルム株式会社 マイクロカプセルの連続的製造方法
US5242684A (en) 1991-10-25 1993-09-07 Isp Investments Inc. Antimicrobial, low toxicity, non-irritating composition comprising a blend of bis-quaternary ammonium compounds coprecipitated with a copolymer of vinylpyrrolidone and an acrylamido or vinyl quaternary ammonium monomer
US5512597A (en) 1991-11-08 1996-04-30 Alcon Laboratories, Inc. Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials
US6051611A (en) 1991-11-08 2000-04-18 Alcon Laboratories, Inc. Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobias
US5559156A (en) * 1993-09-30 1996-09-24 Glaxo Wellcome, Inc. Method for treating animals infected with Babesia spp.
US5530092A (en) 1992-01-13 1996-06-25 Dsm N.V. Dendritic macromolecule and the preparation thereof
CA2094341A1 (en) * 1992-04-28 1993-10-29 Carl W. Porter Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
WO1994000118A1 (en) * 1992-06-19 1994-01-06 The University Of Toledo Production and use of imines of porphyrins
DE4232925A1 (de) * 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
GB9220921D0 (en) 1992-10-05 1992-11-18 Merrell Dow Pharma Polyamine derivatives as anticytomegaloviral agents
EP0664702A1 (en) 1992-10-14 1995-08-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
US5672607A (en) * 1993-01-29 1997-09-30 The United States Of America As Represented By The Department Of Health And Human Services Antiviral naphthoquinone compounds, compositions and uses thereof
DE4306152A1 (de) 1993-02-27 1994-09-01 Hoechst Ag Positiv arbeitendes strahlungsempfindliches Gemisch und damit hergestelltes Aufzeichnungsmaterial
FI955643A7 (fi) * 1993-05-26 1995-11-23 Merrell Pharma Inc N-alkyylitiopolyaminnijohdannaiset säteilyltä suojaavina aineina
US5451347A (en) 1993-06-24 1995-09-19 Lumigen, Inc. Methods and compositions providing enhanced chemiluminescence from chemiluminescent compounds using dicationic surfactants
CA2126889C (en) * 1993-09-02 2005-06-14 Paul R. Hart Method of breaking reverse emulsions in a crude oil desalting system
US5541230A (en) * 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
US5641773A (en) * 1993-11-30 1997-06-24 Dana-Farber Cancer Institute Methods for treating viral infections
ES2119371T3 (es) 1993-12-27 1998-10-01 Novartis Ag Aminocompuestos insaturados para usar como un agente anticancerigeno y antiprotozoico.
US5413719A (en) * 1994-01-18 1995-05-09 Nalco Chemical Company Fluorescent tracer in a water treatment process
JPH09508170A (ja) 1994-01-28 1997-08-19 デーエスエム ナムローゼ フェンノートシャップ 樹枝状高分子物質およびその製造法
DE4403039A1 (de) 1994-01-28 1995-08-03 Schering Ag Oktaazamakrocyclen, deren Metallkomplexe, Verfahren zu deren Herstellung, diese Komplexe enthaltende Mittel sowie deren Verwendung in Diagnostik und Therapie
JPH07228589A (ja) 1994-02-16 1995-08-29 Fuji Photo Film Co Ltd リン酸エステル誘導体およびそれを含有するハロゲン化銀写真感光材料
JPH07277964A (ja) 1994-04-08 1995-10-24 Nippon Kayaku Co Ltd 抗腫瘍剤
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5516807A (en) * 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
EP0789673B1 (en) * 1994-10-31 1998-12-16 Cytec Technology Corp. Methods of coagulating and decolorizing waste streams
CZ143897A3 (cs) 1994-11-12 1998-04-15 Basf Aktiengesellschaft Způsob výroby aminů ze sloučenin obsahujících alespoň tři kyanové skupiny
WO1996022962A1 (en) 1995-01-23 1996-08-01 The Trustees Of Columbia University In The City Of New York Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
FR2729852A1 (fr) 1995-01-30 1996-08-02 Oreal Composition reductrice comprenant un acide amine basique et un polymere cationique
USH1633H (en) * 1995-03-08 1997-02-04 The Lubrizol Corporation Deodorizing polysulfide materials
US5612478A (en) * 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6060604A (en) 1995-03-31 2000-05-09 Florida State University Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US5677349A (en) * 1995-04-27 1997-10-14 Gilad; Gad M. Agmatine for the treatment of neurotrauma and neurodegenerative diseases
US5606053A (en) * 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
WO1996036704A1 (en) * 1995-05-19 1996-11-21 New York Blood Center, Inc. Methods of use of phthalocyanines to inactivate blood borne parasites
EP0752465A1 (en) 1995-06-01 1997-01-08 The Procter & Gamble Company Betaine esters for delivery of alcohols
US5674900A (en) * 1995-06-06 1997-10-07 Shaman Pharmaceuticals, Inc. Terpenoid-type quinones for treatment of diabetes
US5677350A (en) * 1995-06-07 1997-10-14 Wisconsin Alumni Research Foundation Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes
WO1997000910A1 (en) * 1995-06-23 1997-01-09 Exxon Research And Engineering Company Polymer nanocomposite formation by emulsion synthesis
IT1276459B1 (it) 1995-06-30 1997-10-31 Khodor Ammar Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la
US5646188A (en) * 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
US5608061A (en) * 1995-08-02 1997-03-04 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
GB9516929D0 (en) * 1995-08-18 1995-10-18 Ciba Geigy Ag Pigment compositions
WO1997008162A1 (en) 1995-08-24 1997-03-06 Dana-Farber Cancer Institute Beta-lapachone derivatives as antitumor agents
US6136586A (en) 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5869715A (en) 1995-09-27 1999-02-09 The Reagents Of The University Of California Polyfunctional cationic cytofectins
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US5886051A (en) 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5744453A (en) * 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
US5962533A (en) * 1996-02-06 1999-10-05 University Of Florida Research Foundation, Inc. Hydroxy polyamines
AU724312B2 (en) 1996-02-07 2000-09-14 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a salt of dodecylamine and methods of using the same
US5789431A (en) 1996-02-16 1998-08-04 The University Of North Carolina At Chapel Hill Naphthoquinone antitumor compound and method
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
US5883270A (en) 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
JPH09235280A (ja) 1996-02-29 1997-09-09 Kagaku Gijutsu Shinko Jigyodan フラノナフトキノン誘導体と抗腫瘍剤
EP0886524A2 (en) 1996-03-01 1998-12-30 Chiron Corporation Delivery of therapeutic agents to the prostate
DE19611466A1 (de) * 1996-03-25 1997-10-02 Nematel Dr Rudolf Eidenschink Schmiermittel
DE19621510A1 (de) 1996-05-29 1997-12-04 Basf Ag Dendritische stickstoffhaltige organische Verbindungen mit planar-chiralen oder axial-chiralen Endgruppen, ihre Herstellung und Verwendung
US6001573A (en) * 1996-06-14 1999-12-14 Packard Bioscience B.V. Use of porphyrins as a universal label
US6034129A (en) 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
DE19625982A1 (de) 1996-06-28 1998-01-02 Wella Ag Kosmetisches Mittel zur Haarbehandlung mit Dendrimeren
US5866016A (en) 1997-07-01 1999-02-02 Buckman Laboratories International, Inc. Methods and compositions for controlling biofouling using combinations of an ionene polymer and a salt of dodecylamine
US5958397A (en) 1996-07-22 1999-09-28 Schering-Plough Healthcare Products, Inc. Method and composition for protecting against jellyfish stings
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2001501601A (ja) 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド 前立腺ガンの治療において有用な共役体
CA2264745C (en) 1996-09-13 2003-11-11 University Of Florida Research Foundation, Inc. Method of inhibiting biosynthesis of eif5a
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
EP0934249B1 (en) * 1996-10-18 2002-03-27 Wisconsin Alumni Research Foundation Conformationally restricted polyamines and their use as antineoplastic agents
EP0889112A1 (en) 1996-10-22 1999-01-07 Tonen Corporation Lubricating oil composition for automatic transmissions
WO1998025884A1 (en) 1996-12-13 1998-06-18 Cancer Research Campaign Technology Limited Further anthraquinones with biological activity
GB9625941D0 (en) 1996-12-13 1997-01-29 Cancer Res Campaign Tech Anthraquinones with biological activity
US5763388A (en) * 1996-12-18 1998-06-09 Dsm Copolymer, Inc. Process for producing improved silica-reinforced masterbatch of polymers prepared in latex form
WO1998030102A1 (en) * 1997-01-09 1998-07-16 Emory University Non-iron metalloporphyrins and methods of use
JPH10204040A (ja) 1997-01-24 1998-08-04 Daicel Chem Ind Ltd 脂環式ポリアミン類およびその製造方法
EP0988037A1 (en) 1997-02-05 2000-03-29 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
DE19706490C1 (de) * 1997-02-19 1998-09-17 Deutsches Krebsforsch Verfahren zur Herstellung von Säureamiden und zur Metallierung von Verbindungen und Verwendung der nach den Verfahren hergestellten Verbindungen
US5843959A (en) * 1997-03-19 1998-12-01 University Of Florida Research Foundation, Inc. Methods and bicyclic polyamine compositions for the treatment of inflammation
US6235794B1 (en) 1997-04-03 2001-05-22 University Of Florida Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment
US6265540B1 (en) * 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
US6372205B1 (en) 1997-06-11 2002-04-16 The School Of Pharmacy, University Of London Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
JP4044728B2 (ja) * 1997-07-15 2008-02-06 メディクエスト セラピューティックス インク 治療および診断薬剤としての新規なポリアミンアナログ
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
WO1999013920A2 (de) 1997-09-18 1999-03-25 Schering Aktiengesellschaft Verfahren zur therapeutischen behandlung proliferativer erkrankungen
US6436365B2 (en) * 1997-09-23 2002-08-20 Schering Aktiengesellschaft Process for therapeutic treatment of proliferative diseases
DE19744004C1 (de) 1997-09-26 1999-07-22 Schering Ag Lipophile Metall-Komplexe für Nekrose und Infarkt-Imaging
DE19744003B4 (de) * 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
US6093564A (en) 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US5889061A (en) * 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US6307102B1 (en) 1997-10-15 2001-10-23 Tosoh Corporation Amine catalyst for producing polyurethane and polyisocyanurate
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
DE19845782C1 (de) 1998-09-22 2000-04-13 Schering Ag Verfahren zur Herstellung von Metallporphyrin-Metallkomplex-Konjugaten
US6046282A (en) 1998-01-06 2000-04-04 Air Products And Chemicals, Inc. Reactive diluents for polyamidoamine epoxy curatives
CA2321200A1 (en) 1998-02-27 1999-09-02 Dnavec Research Inc. Composition for transporting negatively charged substances
AU7131698A (en) 1998-04-21 1999-11-08 Ilex Oncology, Inc. Polyamine transport inhibitors
DE19825512A1 (de) 1998-06-02 1999-12-09 Schering Ag 3-,8-subsituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel, Verfahren zu ihrer Herstellung und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
JP3996274B2 (ja) 1998-07-07 2007-10-24 電気化学工業株式会社 モノビニルアセチレンの製造方法
DE19835082A1 (de) 1998-07-24 2000-02-03 Schering Ag Paramagnetische 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel, Verfahren zu ihrer Herstellung und ihre Verwendung für das Nekrose- und Infarkt-MR-Imaging
WO2000006136A2 (en) 1998-07-31 2000-02-10 The Health Research, Inc. Therapeutic combination of polyamine with an anticancer agent
GB9817383D0 (en) 1998-08-10 1998-10-07 Ass Octel Diesel fuel compositions
DE19845798A1 (de) 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
WO2000028998A1 (en) 1998-11-16 2000-05-25 Rohto Pharmaceutical Co., Ltd. Liquid ophthalmic preparations
US6174858B1 (en) * 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP3747355B2 (ja) 1998-12-21 2006-02-22 独立行政法人理化学研究所 鎖状ポリアミン系化合物及びポリアミン系抗ガン剤
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
US6649587B1 (en) * 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
DE60029944T2 (de) * 1999-04-30 2007-04-05 Cellgate, Inc., Redwood City Polyamine und ihre therapeutische verwendung
EP1185493B1 (en) * 1999-04-30 2005-07-20 SLIL Biomedical Corporation Quinones for treatment of diseases
IL146126A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6673890B1 (en) 1999-07-16 2004-01-06 Basf Aktiengesellschaft Zwitterionic polyamines and process for their production
GB9920107D0 (en) 1999-08-26 1999-10-27 Avecia Ltd Fluidising agents
FR2802817B1 (fr) 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
WO2001051603A2 (en) 2000-01-10 2001-07-19 Zetetic Research, Inc. Pharmaceutical composition and method of using the same
US6494944B1 (en) 2000-03-02 2002-12-17 Akzo Nobel N.V. Amine oxides as asphalt emulsifiers
FI112796B (fi) 2000-04-14 2004-01-15 Valtion Teknillinen Menetelmä oligo-/polymeripihkahappoaimididendrimeerien valmistamiseksi ja niiden käyttö
US6444707B1 (en) 2000-08-22 2002-09-03 West Agro Topically applied hoof treatment composition and concentrate
AU2001294557A1 (en) 2000-09-11 2002-03-26 Merck And Co., Inc. Thrombin inhibitors
ATE424817T1 (de) 2000-09-19 2009-03-15 Dermal Therapy Barbados Inc Topische analgetische zusammensetzungen enthaltend aliphatische polyamine und methoden für ihre verwendung
US6545181B1 (en) 2000-10-24 2003-04-08 Pilot Chemical Holdings, Inc. Demulsifying compound and a method of breaking or inhibiting emulsions
CA2429982C (en) 2000-12-01 2010-07-13 Ning Li Copper chelators for treating ocular inflammation
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
US6399662B1 (en) 2000-12-13 2002-06-04 University Of Florida Method and composition for the treatment of diarrhea and gastrointestinal spasms
WO2002062341A1 (en) 2001-02-07 2002-08-15 University Of Florida Method and composition for the control of hair growth
US6635679B2 (en) 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
WO2003013245A1 (en) * 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6713653B2 (en) 2001-08-24 2004-03-30 E. I. Du Pont De Nemours And Company Polyamines and polymers made therewith
US20030130356A1 (en) 2001-10-16 2003-07-10 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
US6458795B1 (en) 2001-11-15 2002-10-01 University Of Florida Method and composition for treatment of irritable bowel disease
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
WO2003066572A1 (en) 2002-02-07 2003-08-14 Wisconsin Alumni Research Foundation Polyamine compounds and compositions for use in conjunction with cancer therapy
US6881732B2 (en) 2002-06-13 2005-04-19 Chelator Llc Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
US20040019043A1 (en) 2002-07-23 2004-01-29 Dimitri Coucouvanis Thiomolybdate analogues and uses thereof

Also Published As

Publication number Publication date
US20090275664A1 (en) 2009-11-05
WO2000066175A2 (en) 2000-11-09
WO2000066175A3 (en) 2001-08-02
JP2002543163A (ja) 2002-12-17
US20080194697A1 (en) 2008-08-14
US20040006049A1 (en) 2004-01-08
MXPA01011008A (es) 2003-06-30
CA2368801A1 (en) 2000-11-09
IL146126A (en) 2007-12-03
IL146126A0 (en) 2002-07-25
JP2007204493A (ja) 2007-08-16
US7279502B2 (en) 2007-10-09
US20050233943A1 (en) 2005-10-20
AU4678300A (en) 2000-11-17
EP1173223A2 (en) 2002-01-23

Similar Documents

Publication Publication Date Title
BR0010700A (pt) Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
BR9917007A (pt) Moduladores de ccr5
PE20250839A1 (es) Proteinas y conjugados de union al receptor de transferrina
BR9814276A (pt) Antìgenos de superfìcie
TR199800767T2 (xx) Proteaz engelleyicileri.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR9916585A (pt) Moduladores de ccr5
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
SV1999000096A (es) Calcio (3s) de propilcarbamato tetrahidro 3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonilo] (isobutilo) amino]-1-bencilo-2-+fosfonooxilo ref. pg3508/sv/0
BR9905977A (pt) Moduladores de ccr5
DE69939036D1 (de) PEG Konjugate von LHRH Analogen
IL199497A0 (en) Polypeptide conjugate comprising human factor vii or human factor viia like molecules, nucleotide sequence encoding therefor, method for production thereof, and uses thereof
BRPI0417341A (pt) fator ix glicopeguilado
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
ATE438618T1 (de) Inhibitoren von humanem adam-10
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
MX9601368A (es) Metodo de tratamiento de la reestenosis por terapia genica.
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR9815116A (pt) Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SLIL BIOMEDICAL CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060158970/RJ DE 18/10/2006.

B25A Requested transfer of rights approved

Owner name: CELLGATE, INC. (US)

Free format text: TRANSFERIDO DE: SLIL BIOMEDICAL CORPORATION

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.

B15K Others concerning applications: alteration of classification

Ipc: C07D 295/185 (2006.01), A61K 47/65 (2017.01), C07C